Lemborexant Use for Cognition Improvement in Postoperative Delirium in Elderly Patients: A Randomized Controlled Trial

ConditionPostoperative Delirium

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age60+

SponsorBeijing Tiantan Hospital

About this trial

This prospective, randomized controlled trial aims to investigate the perioperative use of lemborexant, an orexin receptor antagonist, for reducing postoperative delirium (POD) in elderly patients undergoing general anesthesia.

Eligibility criteria

Qualifiers

Age ≥60 years old;

ASA classification I to III;

Patients undergoing elective surgery;

Sign the informed consent form.

Disqualifiers

Tracheal intubation is expected to be retained after the operation;

Previous history of alcohol or drug abuse;

Severe abnormalities in liver and kidney functions;

Long-term use of sedative-hypnotic drugs;

Trial design

Treatments tested in this trial

Lemborexant Pill
Placebo tablet

Treatment groups

992 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Beijing Tiantan Hospital

Lead sponsor

Source ClinicalTrials.gov